Affinity Clinical Research
Latest News and InformationAdverse events – Should I be scared?
When discussing a trial with a potential participant, the discussion will always include the risks and benefits. With trials involving a medicine or drug therapy, there is a risk of side effects and it is essential these are discussed with potential participants...
3 Ingredients for Successful Research
There are three things you need for successful research: A quality Protocol; An engaged Clinician; Motivated Participants/Patients.
Managing Director selected as a finalist for National Awards
Krys Hiscock, Managing Director of Affinity Clinical Research Services, has been selected as a finalist for the 2019 AusMumpreneur Awards in the B2B Service Business Category. The AusMumpreneur Awards presented by AusMumpreneur and The Women’s Business School...
Why it is Essential to have Patient Input into Clinical Trial Design
The Iqvia Institute released a report last month titled The Changing Landscape of Research and Development Innovation1. The report is a fascinating insight into the world of clinical research and provides evidence to support what many in the industry already know:...
Hereditary Haemochromatosis Trial meets Primary Endpoint
Last Thursday, La Jolla Pharmaceuticals issued a press release stating that the results of the Interim Analysis of the LJ401-HH01 (HERCULES) study confirmed the study had met its primary endpoint. The change in Transferrin Saturation (TSAT) from baseline to the end of...
Immunotherapy – An overview
Immunotherapy is a growing therapeutic area for the treatment of cancer both in Australia and other countries and refers to any treatment that uses the patient’s natural defence system (immune system) to fight cancer2. Several Checkpoint Inhibitors have been approved for use in Australia in the last few years, including pembrolizumab, nivolumab and ipilimumab.
First Patient Enrolled in HCC trial
Affinity Oncology reached another milestone today by enrolling its first Hepatocelluar Carcinoma (HCC) patient into a clinical trial. Liver cancer is the sixth most common cancer in the world, and hepatocellular carcinoma (HCC) is the most common type of liver...
How Affinity Works
Affinity is NOT a one-size-fits-all company. We tailor our services to the individual medical practitioner and to the research project. Research with Affinity does not look the same as the traditional research institution. One example of how Affinity works can be seen...
Investigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
Staffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the...
Adverse events – Should I be scared?
When discussing a trial with a potential participant, the discussion will always include the risks and benefits. With trials involving a medicine or drug therapy, there is a risk of side effects and it is essential these are discussed with potential participants...
3 Ingredients for Successful Research
There are three things you need for successful research: A quality Protocol; An engaged Clinician; Motivated Participants/Patients.
Managing Director selected as a finalist for National Awards
Krys Hiscock, Managing Director of Affinity Clinical Research Services, has been selected as a finalist for the 2019 AusMumpreneur Awards in the B2B Service Business Category. The AusMumpreneur Awards presented by AusMumpreneur and The Women’s Business School...
Why it is Essential to have Patient Input into Clinical Trial Design
The Iqvia Institute released a report last month titled The Changing Landscape of Research and Development Innovation1. The report is a fascinating insight into the world of clinical research and provides evidence to support what many in the industry already know:...
Hereditary Haemochromatosis Trial meets Primary Endpoint
Last Thursday, La Jolla Pharmaceuticals issued a press release stating that the results of the Interim Analysis of the LJ401-HH01 (HERCULES) study confirmed the study had met its primary endpoint. The change in Transferrin Saturation (TSAT) from baseline to the end of...
Immunotherapy – An overview
Immunotherapy is a growing therapeutic area for the treatment of cancer both in Australia and other countries and refers to any treatment that uses the patient’s natural defence system (immune system) to fight cancer2. Several Checkpoint Inhibitors have been approved for use in Australia in the last few years, including pembrolizumab, nivolumab and ipilimumab.
First Patient Enrolled in HCC trial
Affinity Oncology reached another milestone today by enrolling its first Hepatocelluar Carcinoma (HCC) patient into a clinical trial. Liver cancer is the sixth most common cancer in the world, and hepatocellular carcinoma (HCC) is the most common type of liver...
How Affinity Works
Affinity is NOT a one-size-fits-all company. We tailor our services to the individual medical practitioner and to the research project. Research with Affinity does not look the same as the traditional research institution. One example of how Affinity works can be seen...
Investigator-Initiated Research – Common Mistakes
Investigator-Initiated research is exciting research. It is attempting to answer questions asked by those at the coal face. Who better than clinicians to know what problems face our patient day-to-day? I have been involved with Investigator-Initiated research for...
Staffing Clinical Trials
The biggest expense of a research project is people. Hiring qualified, experienced staff is not cheap. It is, however, necessary. Without the right people, it is unlikely the research project will make it out of the starting gates, let alone to the...